奥锐特：原料药生产线通过药品GMP符合性检查

Core Viewpoint - The company received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, indicating that its production facilities will be inspected in November 2025, and the results are expected to have no significant impact on performance [1] Group 1: Inspection Details - The inspection will take place from November 12 to 14, 2025, at the company's production site in Tiantai County, Zhejiang, covering workshops 806, 863, and 802, as well as related production lines [1] - The inspection involves the active pharmaceutical ingredients mometasone furoate and betamethasone, with the conclusion indicating compliance with relevant requirements [1] Group 2: Sales Performance - In 2024, the sales revenue for mometasone furoate formulations is projected to be 1.43 billion yuan, while betamethasone formulations are expected to generate 15 million yuan [1] - The company notes that product sales are influenced by multiple factors, leading to inherent uncertainties [1]